ulcerative colitis

News

MSD is paying $20m upfront to activate an alliance with Flagship's Quotient Therapeutics to find new targets in inflammatory bowel disease.

News

Earendil has raised an impressive $787m in financing for its AI-powered drug platform, attracting yet more buy-in from Sanofi.

R&D

Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.

News

Boehringer Ingelheim has sourced an IL-23p19xTL1A bispecific antibody for inflammatory bowel disease, from China's Simcere, for €42m upfront.

News

Shares in Abivax were tracking up this morning as a media report in France suggested it could see a €15bn takeover offer from Eli Lilly.

News

Vedanta's microbiome therapy for ulcerative colitis has failed a phase 2 trial and will be shelved, prompting a 20% cut in workforce.